Cytacon 50micrograms Tablets
Cyanocobalamin 50micrograms Tablets
Each tablet contains 50 micrograms Cyanocobalamin BP.
Excipient(s) with known effect
For the full list of excipients, see section 6.1.
Recommended Clinical Indications:
Treatment of nutritional Vitamin B12 deficiency.
Treatment of vitamin B 12 deficiency following partial gastrectomy.
Treatment of tropical sprue, alone or with folic acid.
Treatment of pernicious anaemia when parenteral administration is not possible or not advised.
The normal dose for adults is appropriate for the elderly.
One to three tablets (50 to 150 micrograms) or more daily at the discretion of the physician.
In pernicious anaemia intramuscular therapy is preferable for initial correction of vitamin B12 deficiency. However, if necessary, the oral route may be used to follow this, in which case at least 300 micrograms should be given daily
One tablet (50 micrograms) daily at the discretion of the physician.
When possible, This medicine doses should be taken between meals.
Method of administration: Oral.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to the product or any of the excipients.
For pernicious anaemia, an adequate dose must be used and the blood picture must be examined regularly at least every three months for 18 months until stabilised, and then annually.
Indiscriminate administration of this medicine may mask precise diagnosis.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Absorption may be reduced by Para-aminosalicylic acid, colchinine, biguanides, neomycin, cholestyramine, potassium chloride, methyldopa, and cimetidine.
Patients treated with chloramphenicol may respond poorly to this medicine.
Serum levels of this medicine may be lowered by oral contraceptives. These interactions are unlikely to have clinical significance.
Anti-metabolities and most antibiotics invalidate vitamins B12 assays by microbiological techniques.
This medicine should not be used to treat megaloblastic anaemia of pregnancy because this is due to folate deficiency.
Sensitisation to this medicine is rare, but may present as an itching exanthema, and exceptionally as anaphylactic shock.
Acneform and bullous eruptions have been reported rarely.
Patients who have become sensitised to this medicine by injection are often able to tolerate the oral route without trouble.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdosage is unlikely to require treatment.
This medicine contain cyanocobalamin vitamin B 12, which is used for the treatment of pernicious anaemia, and nutritional deficiencies of vitamin B 12 which results in macrocytic anaemia.
ATC code: B03BA01
The absorption of cobalamins from the gut is dependent upon the glycoprotein intrinsic factor.
Cobalamins are transported rapidly into the blood bound to protein, known as transcobalamins.
Cobalamins are stored in the liver and excreted in the bile. They are known to cross the placenta.
No further relevant data.
24 months in securitainers.
24 months in blisters
Store below 25°C. Store in the original container in order to protect from light. Keep the container tightly closed.
Store below 25°C, protected from light.
Polyproylene container with a tamper evident low density polyethylene lid, containing 50 or 100 Cyanocobalamin Tablets.
Tampertainer staysafe made from high density polyethylene containing 50 or 100 tablets.
PVC/PVdC /Aluminium blister packs with 28, 56 or 112 tablets.
Mercury Pharma Group Ltd
Capital House, 85 King William Street,
London EC4N 7BL, UK